Full title: Surveillance of pAncreatic health aFter diabEtes Diagnosis
This is a randomised trial to evaluate the cfDNA Pancreatic Cancer test (Avantect) in the early detection of pancreatic cancer in patients with newly diagnosed diabetes mellitus.
Who is eligible to take part?
You are eligible if you have been diagnosed with type 2 diabetes in the past 6 months and aged between 50 to 84 yrs.
Pancreatic cancer is damages insulin producing cells similar to diabetes. So people diagnosed with diabetes have a higher chance who being diagnosed with pancreatic cancer. Currently there is no screening test for pancreatic cancer. This new Avantect test is designed to detect the possible presence of pancreatic cancer at an early treatable stage, long before symptoms become apparent.
If you are interested in more information, the study website goes deeper the what is involved in the study and if you think you are eligible, you can express your interest there.
Study Website: https://safe-d.uk/
Full Title: A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
Aim: This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
We are now recruiting participants for this study. If you think you are eligible or know someone who may be eligible, please email hcl.trials@nhs.net
| Could I be eligible to take part? | |
 You must |  You must not |
| – Be aged between 40-80 years. – Have good inhaler-use technique. – Be diagnosed with COPD. – Be a current or former smoker. Have a cardiovascular risk. | – Have any other respiratory condition aside from COPD. – Have had a heart or lung transplant or actively be listed for a transplant. – Have a history of lung cancer and/or treatment for this in the last 5 years. – Have used maintenance Inhaled Corticosteroids in the last 12months. – Be unable to comply with study procedures, restrictions, or requirements. – Be a currently pregnant female. |
Full Title: A pivotal, randomized, placebo-controlled, double-blind, multicenter, international Phase III clinical trial is designed to investigate the efficacy and safety of ALLO-APZ2-CVU in promoting wound healing in patients with therapy-resistant, non-healing chronic venous ulcers (CVUs).
Aim: To evaluate the efficacy and safety of topically administered allo-APZ2-CVU compared to a placebo. This study aims to improve treatment outcomes for patients suffering from therapy-resistant CVUs
If you think you have any patients eligible for this study please email hcl.trials@nhs.net
You can read more about FAQs about this study here
Full Title: A Phase 3, multicenter, randomized, double‐blind, placebo-controlled, parallel‐group study to evaLuate the effIcacy and safety of abeLacimab in high‐risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)
The HCL research team is now participating in this study, which investigates the use of abelacimab for stroke prevention in patients with atrial fibrillation who can’t have DOACs either through choice or increased bleed risk (eg, frailty, renal impairment, previous GI bleeds, on antiplatelets, high HAS-BLED score).
Abelacimab is a monoclonal antibody which targets factor XI and so reduces stroke risk without a substantial increase in bleed risk. In the AZALEA–TIMI71 study, abelacimab was shown to be associated with only one-third of the bleeding rate compared to rivaroxaban.
We are looking for participants who may be able to benefit from a trial of this revolutionary new medication and need your help identifying them.
We are looking for patients with:-
- A diagnosis of atrial fibrillation
- and 65 years or older
- and not on a DOAC (either by patient choice or clinically high risk for a blood eg frailty, renal impairment, previous GI bleeds, taking antiplatelets, high HAS-BLED score)
If you have any patients which meet this criteria or have any queries, please email us at hcl.trials@nhs.net
Full title: Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events
More than one in three adults aged 75+ years are prescribed five or more drugs to treat their long-term conditions. People who take lots of drugs are more likely to end up with reduced independence and quality of life as they get older. They are also more likely to end up in hospital due to drug side effects. One solution is to stop or ‘deprescribe’ drugs which no longer provide benefit, or could be potentially harmful.
The most commonly prescribed drugs in older people are those used to lower blood pressure. These drugs reduce the risk of a stroke and heart attack. However, in some frail older people, they might also be harmful, causing kidney problems and fainting (leading to serious falls). This could cancel out any potential benefits of treatment. This uncertainty makes blood pressure lowering drugs an ideal target for deprescribing.
The aim of this trial will establish whether deprescribing common drugs that lower blood pressure is safe in older people. We will answer:
1. What is the effect of deprescribing blood pressure lowering drugs on hospital admissions and overall health outcomes?
2. Does deprescribing improve quality of life and/or save money for the NHS?
If you are registered in these 3 practices; Fitzrovia Medical Practice, Cavendish Health Centre and Pimlico Health at the Marven and think you might be eligible, please let us know at hcl.trials@nhs.net.
Full title: Effectiveness of Electronic Cigarettes compared with combination nicotine replacement therapy for smoking cessation in patients with chronic obstructive pulmonary disease And effect on Lung health (ECAL trial)
The main objective of this study is to find out how effective e-cigs are compared with combination nicotine replacement therapy (NRT) in helping Chronic Obstructive Pulmonary Disease (COPD) patients quit smoking cigarettes, and which treatment is more cost-effective for the National Health Service (NHS).
Along with the main objective, the study also has a lung health sub-study that aims investigate the effect of switching from smoking to exclusive EC use on clinical, physiological and cellular lung health measures compared with (1) quitting smoking without vaping and (2) continuing to smoke in patients with COPD.
Wellbeing sub-study aims and objectives: To investigate the effect of switching from smoking to exclusive EC use on anxiety, depression and social quality of life compared with (1) quitting smoking without vaping and (2) continuing to smoke in patients with COPD.
For more information or if you are interested in the study please follow this link CLICK HERE
Faecal calprotectin (FC) serves as a calcium-binding cytosolic protein secreted by neutrophils, finding wide application as a screening tool for gastrointestinal inflammation. Numerous studies have highlighted elevated FC levels in patients with inflammatory bowel disease (IBD) compared to control groups like those with irritable bowel syndrome (IBS). Its utility extends to IBD management due to its correlation with disease activity markers. The cost-effectiveness of FC testing and its potential to reduce unnecessary referrals to secondary care have resulted in its widespread adoption in primary care settings. As a stable protein constituting a significant portion of neutrophil cytosolic content, calprotectin is released into feces during gastrointestinal inflammation, offering a non-invasive, cost-effective, and objective means of assessing patients before considering more invasive procedures such as colonoscopy or imaging studies. A prospective study will be conducted to assess the utility of faecal calprotectin (FC) testing in primary care settings, focusing on patients referred for this test. Baseline clinical information will be collected from recruited patients, and the Bristol Stool Scale score will be noted on the faecal samples sent for FC testing to gauge stool consistency. Participants will be followed up over a one-year period to track the outcomes of subsequent investigations, aiding in the determination of appropriate FC cut-off values and evaluating the impact of stool consistency on FC diagnostic efficacy. This research aims to address existing concerns regarding FC testing, particularly its application in primary care and the need for clearer cut-off values. By prospectively investigating FC utility and re-evaluating its cut-off value, this study seeks to enhance diagnostic accuracy in distinguishing between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and streamline referral pathways for patients presenting with gastrointestinal symptoms.
For more information click here